# Aethlon Medical (AEMD) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/AEMD
## Company Profile
- Ticker: AEMD
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: MedTech, Oncology
## Stock Data
- Close: 3.02 USD
- Market cap: 3467733.1 USD
- Last updated: 2026-08-06
## Business Overview
### Clinical-Stage Medical Device Company
Aethlon Medical is developing the Hemopurifier, an extracorporeal device designed to remove enveloped viruses and tumor-derived extracellular vesicles from blood. The company is pursuing applications in oncology, life-threatening viral infections, and other inflammation-associated diseases.
### Hemopurifier Mechanism
The Hemopurifier combines plasma separation, size exclusion, and affinity binding using a plant-derived lectin resin that targets mannose-rich structures on extracellular vesicles and viral surfaces. Tumor-derived EVs are believed to contribute to metastasis and resistance to immunotherapy and chemotherapy.
### Oncology and Infectious Disease Platform
The same extracorporeal filtration approach may be applicable across diseases involving circulating pathogenic particles. Aethlon is currently prioritizing tumor-derived EV removal in oncology while retaining potential applications in severe enveloped viral infections.
### Oncology Development Path
Aethlon is conducting an Australian study in patients with solid tumors whose disease is stable or progressing on anti-PD-1 therapy. The first two dose cohorts have been completed, and treatment has begun in the third and final cohort.
## Why The Stock Is Moving

Following the latest company update, “Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026”, AEMD closed down 7.67% at $3.25 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Completion of enrollment and analysis of all dosing regimens in Cohort 3 of the Australian oncology study are the next clinical milestones.
- Cohort 3 results are expected to help define the optimal Hemopurifier treatment regimen and guide future oncology development.

## Recent News
- 2026-08-05 12:01 EST — [Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026](https://biopharmsignal.com/news/AEMD/aethlon-medical-to-release-first-quarter-financial-results-and-host-conference-c-9569497a) — Source: Aethlon Medical
- 2026-07-13 12:01 EST — [Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®](https://biopharmsignal.com/news/AEMD/aethlon-medical-continues-to-observe-directional-changes-in-second-cohort-of-aus-9cc3f8f7) — Source: Aethlon Medical
- 2026-07-06 13:25 EST — [Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules](https://biopharmsignal.com/news/AEMD/aethlon-medical-announces-pricing-of-4-0-million-follow-on-offering-priced-at-th-e3315678) — Source: Aethlon Medical
- 2026-06-26 12:01 EST — [Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®](https://biopharmsignal.com/news/AEMD/aethlon-medical-announces-publication-demonstrating-novel-long-covid-biomarker-a-2129c0c1) — Source: Aethlon Medical
- 2026-06-10 20:15 EST — [Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update](https://biopharmsignal.com/news/AEMD/aethlon-medical-announces-fiscal-year-end-march-31-2026-financial-results-and-co-7600574b) — Source: Aethlon Medical